NCT03397537View on ClinicalTrials.gov

Neoadjuvant Endocrine Therapy in Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Highly Endocrine Responsive Operable Breast Cancer
Interventions
DRUG

Letrozole 2.5Mg Tablet

letrozole 2.5mg p.o.qd

DRUG

GnRH analogue

3.75 mg triptorelin im. q28d

Trial Locations (1)

510080

Minyi Cheng, Guanzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER

NCT03397537 - Neoadjuvant Endocrine Therapy in Breast Cancer | Biotech Hunter | Biotech Hunter